RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin

NCT00485342 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

236

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Peg-interferon alpha 2a and ribavin
DRUG: ribavirin with adaptation dose

Sponsor

Hospices Civils de Lyon